A group of prominent AI companies is calling on Congress to establish protections for DNA data, highlighting the importance of safeguarding genetic information in the age of advanced technology.
The partnership between Inceptive Nucleics and Alnylam is part of a broader trend in the biotech sector, which seeks to innovate while addressing ethical concerns related to genetic data.
Additionally, the implications of Grail's recent trial, despite being labeled a failure, continue to spark discussions about the future of genetic testing and its regulatory landscape.